Ezedigwe Sonsochukwu Godfrey

Ezedigwe Sonsochukwu Godfrey

Auto-generated profile, based on publicly available information

Ezedigwe Sonsochukwu Godfrey

Faculty of Pharmaceutical Sciences, University College Hospital, Ibadan, Nigeria

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
RARehab Emad Ashmawy
Rehab Emad Ashmawy
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
BUBonaventure Ukoaka
Bonaventure Ukoaka
FDFaithful Miebaka Daniel
Faithful Miebaka Daniel
SESonsochukwu Godfrey Ezedigwe
Sonsochukwu Godfrey Ezedigwe
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
Background: Alzheimer's disease (AD) is a growing neurodegenerative disorder causing cognitive decline, memory loss, and functional impairment. Lecanemab has shown safety and efficacy in clinical trials. Objective: This review aims to understand the clinical evidence of lecanemab's effectiveness and safety in managing early AD. Methods: A systematic search was conducted using the Scopus database and ClinicalTrials.gov. Studies from 2014 to 2024 on lecanemab's safety, efficacy, and clinical outcomes for AD were included. Data extraction involved two independent reviewers, with synthesis using qualitative methodology. Results: Findings from 13 studies and 13 ongoing clinical trials were reported, showing that lecanemab substantially reduces amyloid plaque load in the brains of AD patients. The therapeutic regimens vary across reported studies and trials, ranging from 2.5 mg/kg biweekly, 5 mg/kg monthly, 5 mg/kg biweekly, 10 mg/kg monthly, and 10 mg/kg intravenously biweekly. The Clarity AD phase 3 trial, the AHEAD study, and the DIAN-TU-001 trials have reported positive study outcomes with robust efficacy and safety outcomes with minimal side effects. Completed and ongoing trials report on the onset of amyloid-related imaging abnormalities (ARIA) and the continuation of care status following the onset of ARIA in these patients. The common infusion-related reactions were observed in 26.4% of the lecanemab group compared to 7% in the placebo group. Conclusions: The management of AD has evolved over the years with the introduction of novel therapeutic agents like lecanemab. While its safety profile is generally favorable, careful monitoring is essential.

17 October 2025 in INNOVATIONS in pharmacy
Verified
Journal Article
Open access
PDF file
JTJulia Tanimojo
Julia Tanimojo
OOOladotun Okediji
Oladotun Okediji
AAAishat Adebayo
Aishat Adebayo
NUNora Ugwuanyi
Nora Ugwuanyi
SGSamad Garuba
Samad Garuba
VAVivian Anakudo
Vivian Anakudo
Innovations in Pharmacy is closed for submissions.  Thank you to our readers, authors, reviewers and editors, as well as U of M Publishing Services, for supporting 16 years of publishing! Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.

22 October 2025 in Asia Pacific Journal of Public Health
Verified
Journal Article
Closed access
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
MAMohamed Mustaf Ahmed
Mohamed Mustaf Ahmed
OOOlanegan Gloria Oluwakemi
Olanegan Gloria Oluwakemi
TOTolutope Adebimpe Oso
Tolutope Adebimpe Oso
LOLawal Azeez Okikiola
Lawal Azeez Okikiola
DLDon Eliseo Lucero-Prisno
Don Eliseo Lucero-Prisno